GSK PLC Sponsored ADR (NYSE:GSK) Shares Acquired by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. grew its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 12.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 358,482 shares of the pharmaceutical company’s stock after buying an additional 38,779 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in GSK were worth $13,888,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GSK. Brighton Jones LLC acquired a new position in GSK during the 4th quarter worth $528,000. Charles Schwab Investment Management Inc. grew its position in shares of GSK by 4.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 126,647 shares of the pharmaceutical company’s stock worth $4,283,000 after buying an additional 5,044 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of GSK by 83.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,189 shares of the pharmaceutical company’s stock worth $142,000 after buying an additional 1,902 shares in the last quarter. Mondrian Investment Partners LTD grew its position in shares of GSK by 17.6% during the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after buying an additional 874,004 shares in the last quarter. Finally, Corient Private Wealth LLC grew its holdings in GSK by 12.8% during the 4th quarter. Corient Private Wealth LLC now owns 96,344 shares of the pharmaceutical company’s stock worth $3,258,000 after acquiring an additional 10,895 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on GSK. Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a report on Monday, April 28th. Berenberg Bank reiterated a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. Finally, BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $37.38.

GSK Trading Down 1.2%

Shares of GSK stock opened at $37.81 on Wednesday. The company has a fifty day simple moving average of $38.97 and a 200-day simple moving average of $37.33. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The stock has a market cap of $77.41 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.54 and a beta of 0.50.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The company had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter in the prior year, the firm posted $0.43 earnings per share. GSK’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were given a $0.4216 dividend. The ex-dividend date was Friday, May 16th. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.46%. GSK’s dividend payout ratio is 87.63%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.